Monitoring differences in the innate and adaptive immune response in Amish and Hutterite children
By Ralph McDade Let your kids get dirty; it’s good for them! In the current issue of the New England Journal of Medicine researchers explore the mec...
Researchers in this immuno-oncology trial used Myriad RBM’s services to measure serum biomarkers.
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma The data presented in this paper shows baseline and on-treatment biomarkers...
Impressions from Biomarkers and Diagnostics World Congress 2016
Our sales and marketing team represented Myriad RBM at the Biomarkers and Diagnostics World Congress in Philadelphia with a booth on the vendor floor....
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia
An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that...
ENRAGE: A Novel Inflammatory Marker for Incident Coronary Heart Disease
This recent paper in the Arteriosclerosis, Thrombosis and Vascular Biology Journal of the American Heart Association describes an interesting prospect...
Blood-based proteins are crucial to the development of biomarker tests aimed at improving the diagnosis and treatment of psychiatric disorders
A recent review of studies measuring proteins in blood serum/plasma illustrates the systemic nature of disease-related changes in patients with schizo...
Biomarker signatures predict clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with chemotherapy and cediranib
Researchers sought to explore biomarkers in pre- and on- treatment mCRC patients receiving chemotherapy with and without cediranib, in order to identi...